Regeneron Pharmaceuticals is appealing a case concerning its EYLEA® drug, which treats eye diseases, as it seeks to prevent the marketing of biosimilar versions. The key legal issues revolve around personal jurisdiction and patent infringement claims against Samsung Bioepis, which is challenging the district court's authority to impose a preliminary injunction. The court initially ruled in favor of Regeneron, granting the injunction based on likely success in its claims, but Samsung Bioepis appealed this decision to the Federal Circuit, questioning the jurisdictional basis for the ruling.
Regeneron secured a preliminary injunction blocking Samsung Bioepis from marketing its EYLEA biosimilars, as Regeneron successfully argued potential patent infringement.
The Federal Circuit is set to review the jurisdictional questions and validity of the preliminary injunction that the district court granted to Regeneron.
Collection
[
|
...
]